Testing for PIK3CA and AKT1 mutations in tumors is important for several reasons, especially in the context of personalized medicine and targeted cancer therapy. PIK3CA and AKT1 are genes involved in the PI3K/AKT/mTOR signaling pathway, which plays a crucial role in...
This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during August 2024 (epidemiological weeks 32-35). The data is dependent on submission of samples by clinicians and therefore may not be...
Autoimmune bullous skin disease (AIBD) is a group of blistering skin disorders caused by autoantibodies directed against various structural proteins of the skin. The main clinical features are blisters and bullae in the skin and mucous membranes, progressing to...
This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during July 2024 (epidemiological weeks 27-31). The data is dependent on submission of samples by clinicians and therefore may not be...
This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during June 2024 (epidemiological weeks 23-26). The data is dependent on submission of samples by clinicians and therefore may not be...
Since May 2022, more than 97 000 cases of mpox have been reported globally from 117 countries, with 186 deaths (as of 31 May 2024). Between June and September of 2022, five cases of mpox were reported in South Africa, with no fatalities. All of these cases reported...
This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during May 2024 (epidemiological weeks 18-22). The data is dependent on submission of samples by clinicians and therefore may not be...
Surveillance is an important tool to guide empiric therapy. Here we present the PathCare susceptibility data for the Eastern Cape for common community pathogens isolated from clinical specimens in 2023. As this data reflects the susceptibility of all isolates,...
This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during April 2024 (epidemiological weeks 14-17). The data is dependent on submission of samples by clinicians and therefore may not be...
This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during March 2024 (epidemiological weeks 10-13). The data is dependent on submission of samples by clinicians and therefore may not be...